(However, this did not translate into deaths and heart attacks, which were lower for Endeavor patients than Taxus ones.) This is not the best time for such news. Endeavor will be discussed by an FDA advisory panel on Wednesday, after which the panel will decide whether to recommend it for approval. Even if Endeavor does get through FDA, the new data gives Boston Scientific marketing ammunition.
0 comments
Hide comments
